A Phase 1-2 ascending dose study to assess the pharmacodynamics, pharmacokinetics, and safety of HSP 130 in subjects with non metastatic breast cancer following single dose and multiple dose administration by subcutaneous injection
Phase of Trial: Phase II
Latest Information Update: 06 Oct 2017
At a glance
- Drugs Pegfilgrastim (Primary)
- Indications Immunodeficiency disorders
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Hospira; Pfizer
- 03 Oct 2017 Planned End Date changed from 1 Sep 2017 to 1 Oct 2017.
- 03 Oct 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Oct 2017.
- 07 Sep 2017 Planned number of patients changed from 48 to 24.